Dr. Senderowicz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9406 Linden Ave
Bethesda, MD 20814Phone+1 301-530-0892
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1992 - 1995
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1990 - 1992
New York-Presbyterian/QueensInternship, Internal Medicine, 1989 - 1990
University of Buenos AiresClass of 1987
Certifications & Licensure
NY State Medical License 1992 - 2025
Publications & Presentations
PubMed
- 285 citationsOverexpression of the ATP-binding Cassette Half-Transporter, ABCG2 (MXR/BCRP/ABCP1), in Flavopiridol-resistant Human Breast Cancer CellsRobert W. Robey, Wilma Y. Medina-Pérez, Kenryu Nishiyama, Tyler Lahusen, Keisuke Miyake
Clinical Cancer Research. 2001-01-01 - 136 citationsPhase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors.Edward A. Sausville, Patricia LoRusso, Michael A. Carducci, Judith Carter, Mary F. Quinn
Cancer Chemotherapy and Pharmacology. 2014-01-22 - 37 citationsBiliary excretion of flavopiridol and its glucuronides in the isolated perfused rat liver: role of multidrug resistance protein 2 (Mrp2).Walter Jäger, E Gehring, Birgit Hagenauer, Sylvia Aust, Adrian M. Senderowicz
Life Sciences. 2003-10-17
Abstracts/Posters
- Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in Combination with Ruxolitinib, in JAK Inhibitor...Adrian Senderowicz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or Add-on to Ruxolitinib, in Patients with Refractory or...Adrian Senderowicz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
New Compounds Targeting Epigenetics Show Promise in Lymphoma PatientsMarch 5th, 2018
Constellation Pharmaceuticals Announces Initiation of Phase 1b/2 Study of CPI-1205 in Combination with Checkpoint InhibitorsJanuary 16th, 2018- Constellation Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 PROSTAR Combination Study of CPI-1205 in Advanced Form of Prostate CancerDecember 12th, 2017
- Join now to see all
Grant Support
- Translational Effects Of Small Molecule Cell Cycle ModulNational Institute Of Dental &Craniofacial Research2003–2004
- Antiproliferative Effects Of Small Molecules: Basic AndNational Institute Of Dental &Craniofacial Research2002–2004
- Antiproliferative Effects Of Small MoleculesNational Institute Of Dental &Craniofacial Research2000–2003
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
